|

media

press releases

2014 press releases
7 october
BioHorizons Introduces MinerOss® X, Family of Xenograft Products
Now offers dentists the most comprehensive grafting portfolio worldwide

BIRMINGHAM, AL, October 7, 2014 --

BioHorizons, an oral reconstructive device company, today announced the launch of MinerOss® X, a family of xenograft products for dental implant site development procedures. The MinerOss® X family includes cancellous or cortical particulate, a moldable collagen block, and a cancellous particulate pre-loaded into a delivery syringe to assist with optimal placement. It is designed for extraction sockets, grafting for implant placement, ridge augmentation, and sinus augmentation.

"MinerOss® X represents a significant addition to our innovative tissue regeneration product portfolio. MinerOss® X is a xenograft alternative for predictable bone regeneration and complements our highly successful line of MinerOss® allografts. With this product line, BioHorizons offers dentists the most complete portfolio of regenerative hard and soft tissue grafting products," said Steve Boggan, President and CEO of BioHorizons.

MinerOss® X particulates range in size from 250 to 1000 microns providing excellent handling characteristics for a wide variety of regeneration procedures. MinerOss® X particulate is available in 0.25g, 0.5g, 1.0g and 2.0g easily accessible vials with a convenient screw-top lid. MinerOss® X syringe is available in 0.25cc, 0.5cc and 1.0cc sizes for added convenience during surgery. MinerOss® X collagen is also available in three sizes to support large and small grafting cases.

About BioHorizons
BioHorizons, Inc., a majority-owned subsidiary of Henry Schein, Inc. (NASDAQ:HSIC), is a leading dental implant and biologics company located in Birmingham, Alabama. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions for the replacement of missing teeth. BioHorizons products are available in 85 markets around the world. For more information, visit biohorizons.com.

6 june
BioHorizons Hosts Dental Delegates from 40 Countries at Recent International Symposium Series

BIRMINGHAM, AL, May 29, 2014 --

BioHorizons, one the fastest growing companies in the dental implant industry, recently hosted the latest event in its 2014 International Symposium Series in Dubai, UAE, May 7-9 at the Madinat Jumeirah, a luxurious 5-star resort and the largest resort in the emirate.

Over 800 delegates from more than 40 countries around the world gathered at this exciting event to discuss the latest issues in implant dentistry and tissue regeneration. The meeting started with three sold out pre-symposium courses featuring: Dr. Edward Pat Allen and his world-recognized soft tissue grafting hands-on workshop; a clinical concepts course on tissue management around Laser-Lok® abutments with Dr. Gerhard Iglhaut; and a comprehensive lecture and hands-on course, TeethXpress: An optimal immediate load treatment solution for edentulous patients, led by Drs. Lewis Cummings and Justin Moody.

Mr. Steve Boggan, President and CEO of BioHorizons, opened the symposium with a welcome message and an update on all the latest company events and news. The scientific program was well recognized with the participation of world-renowned clinicians such as Drs. Marius Steigmann, Thomas Linkevicius, Alain Romanos, Farhad Boltchi, Ken Nicholson, Anthony Summerwill, Jack Ricci, Abd Elsalam Elaskary, Georg Arentowicz, and Martijn Moolenaar. "BioHorizons prides itself on the quality of the continuing education we support. Our International Symposium Series is leading the way with some of the most advanced training and techniques in the industry," said Mark Neri, Vice President of International Sales.

Attendees were impressed with the level of education and fascinated by the venue and the unforgettable experiences during the different social events including a memorable safari to the Arabian Desert, and the BioHorizons Gala held at the Madinat Arena with the presence of over 900 guests who enjoyed exotic international food and the best live entertainment to be found in the city.

BioHorizons will continue its 2014 International Symposium Series with events in Sydney, Australia (Aug. 14-16), Mexico City, Mexico (Oct. 31 and Nov. 1), and Medellin, Colombia (Nov. 21-22). The company's world-renowned, biennial Global Symposium will take place on April 16-18, 2015, in Los Angeles, California, at the J.W. Marriott Los Angeles L.A. Live.

About BioHorizons – BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implant, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons proprietary Laser-Lok® microchannel surface technology. With 25 years of research and 35 published studies or articles, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long term crestal bone maintenance. The BioHorizons portfolio is offered in 85 markets around the world. For more information, visit biohorizons.com.

Contacts
BioHorizons
Veronica Zamora, 205-986-7927
Manager, International Marketing & Education

2013 press releases
31 december
Henry Schein Completes Strategic Investment in Dental Implant Manufacturer BioHorizons

MELVILLE, N.Y., Dec. 31, 2013 /PRNewswire/ --

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today announced the completion of a 60% equity investment in BioHorizons, Inc., a U.S.-based manufacturer of advanced dental implant technology and tissue regeneration products sold globally. This transaction was first announced on November 26, 2013.

Together with the Company's investment in CAMLOG Biotechnologies AG, a leading manufacturer of dental implants in Europe, Henry Schein now has important positions in the U.S. and German implant markets, as well as a growing presence in the rest of the world. The investment in BioHorizons also strengthens Henry Schein's position and product portfolio in the biologics market, which is a critical adjunct to the implant market.

"With the completion of this strategic investment in BioHorizons we have advanced our dental specialties markets business strategy and now have a stronger presence in two of the world's largest markets for dental implants," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Implant dentistry is a critical element of the profession's transition to digital dentistry, and customer demand for implants and the associated materials is expected to increase as digital processes are adopted and the patient's dental experience is enhanced."

"On behalf of the shareholders and management of BioHorizons, we are delighted with the closing of the transaction and the partnership with Henry Schein which combines BioHorizons' impressive growth with Henry Schein's global strengths," said Mortimer Berkowitz III, Chairman of BioHorizons and President of HealthpointCapital, LLC. "We look forward to working with Henry Schein and the BioHorizons team to strengthen our presence in the growing implant dentistry market by continuing to develop differentiated products for our customers."

About BioHorizons
BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. Based in Birmingham, Alabama, the company offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products and surgical planning software.

BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability and high-end, aesthetic outcomes through the use of its proprietary Laser-Lok® microchannel surface technology. With 25 years of research and 30 published studies, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world. For more information, visit the BioHorizons Web site www.BioHorizons.com.

About HealthpointCapital, LLC.
HealthpointCapital is a growth buyout private equity firm which is exclusively focused on the musculoskeletal sector. It was formed in 2002 and has $750 million in assets under management. It became a majority owner of BioHorizons through an acquisition of the Company in 2006. For more information, visit the HealthpointCapital Web site www.healthpointcapital.com

About Henry Schein, Inc.
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs nearly 16,000 Team Schein Members and serves nearly 800,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record $8.9 billion in 2012, and have grown at a compound annual rate of 17% since Henry Schein became a public company in 1995. For more information, visit the Henry Schein Web site at www.henryschein.com.

Cautionary Note Regarding Forward-Looking Statements
In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; possible increases in the cost of shipping our products or other service issues with our third-party shippers; general global macro-economic conditions; disruptions in financial markets; possible volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from rapid technological change; risks from disruption to our information systems; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

SOURCE Henry Schein, Inc.

RELATED LINKS
www.henryschein.com

26 november
Henry Schein signs agreement to invest In BioHorizons

MELVILLE, N.Y., Nov. 26, 2013 /PRNewswire/ --

Company advances strategy to enhance position in dental specialty markets with investment in implant manufacturer

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today plans to make a strategic investment in dental implant manufacturer BioHorizons, Inc., advancing the Company's goal of expanding its position in the dental specialty market.

Henry Schein reached an agreement to acquire a 60% interest in BioHorizons, a U.S.-based manufacturer of advanced dental implants sold internationally. Under the agreement, BioHorizons, with revenue of approximately $115 million, will continue to operate as an independent company. Financial terms of the proposed transaction were not disclosed. The transaction with BioHorizons involves a two-step process: A recapitalization through which Henry Schein will lend approximately $145 million to BioHorizons to fund, among other uses, a distribution to shareholders, which will occur prior to closing, followed by the equity investment. Pending regulatory approval, Henry Schein expects to complete the transaction by the end of the year.

The agreement with BioHorizons strengthens Henry Schein's position in a critical and growing market that also includes the company's investment in CAMLOG Biotechnologies AG, a leading manufacturer of implants in Europe. With these two investments, Henry Schein will have important positions in two of the largest implant markets -- the U.S. and Germany -- as well as a growing presence in the rest of the world. BioHorizons and CAMLOG, which will each operate independently, are strong brands with unique features and benefits that offer customers a broad range of treatment options. The investment in BioHorizons also strengthens Henry Schein's position and product portfolio in the biologics market, a critical adjunct to the implant market. Henry Schein offers customers a wide array of the products and services associated with implant dentistry, thereby providing a complete solution for the benefit of the dental practice.

"Henry Schein's strategy includes advancing our position in dental specialty markets, an integral part of which is to support those practitioners who perform oral surgery involving implants," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Implant dentistry is a critical element of the profession's transition to digital dentistry. More and more abutments for implants are being digitally designed and fabricated, which increase patient comfort and esthetics and reduce patient visits. Customer demand for implants and the associated materials are expected to increase as digital processes are adopted and the dental experience for the patient is enhanced."

The value of the global implant market is expected to reach approximately $4.2 billion in 2016, up from approximately $3 billion in 2012. In the U.S. and Canada, the market is expected to reach $1.5 billion in 2016, up from approximately $1 billion in 2012.

Based in Birmingham, Alabama, BioHorizons employs approximately 325 people and markets its products in 85 markets. Its revenue has been growing on average by more than 10 percent annually, and more than half of that revenue is derived in the U.S. Founded in 1995, the company offers a broad spectrum of innovative products, including implants featuring its proprietary Laser-Lok(R) microchannel surface technology, designed to minimize bone loss and maximize esthetics.

"On behalf of the shareholders and management of BioHorizons, we are delighted with this partnership, which combines BioHorizons' record of global growth and clinical excellence in the implant dentistry field with Henry Schein's strengths worldwide," said Mortimer Berkowitz III, Chairman of BioHorizons. "Having known the Henry Schein management team for some years, we look forward to working closely with them to build the business into a global leadership position by delivering outstanding patient results through differentiated products."

BioHorizons benefits from a long-serving management team. The company will continue to be led by its President and CEO, Steve Boggan, who has held that position since 1999; Todd Strong, Executive Vice President and Chief Operating Officer, who joined BioHorizons at its founding in 1995; and David Wall, Executive Vice President and Chief Financial Officer. BioHorizons will be a part of Henry Schein's Global Dental Surgical Group, and its revenue will be reported as part of the Company's Global Dental Group.

"We believe our partnership with Henry Schein will further enhance our growth prospects in the implant and biologics market," said Mr. Boggan. "The strength of Henry Schein and its deep relationships in the marketplace create an ideal combination. We are looking forward to advancing the goals of both organizations, and are very pleased to be part of Team Schein."

2014 Guidance
Henry Schein expects the BioHorizons transaction to be dilutive to earnings per share in 2014 by $0.03 to $0.05, and accretive to earnings per share in 2015 by $0.03 to $0.04. The 2014 dilution is primarily due to a one-time inventory revaluation as required under U.S. GAAP accounting rules for business combinations. Together with the previously announced definitive agreement to acquire 80% of Poland's Medivet S.A., the Company has revised its 2014 financial guidance, as follows:

-- For 2014, the Company now expects diluted EPS attributable to Henry Schein, Inc. to be $5.32 to $5.42, which represents growth of 9% to 11% compared with the midpoint of the 2013 guidance range.

-- Guidance for 2014 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

About BioHorizons
BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons' proprietary Laser-Lok(R) microchannel surface technology. With 25 years of research and 30 published studies, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world. For more information, visit www.biohorizons.com.

About Henry Schein, Inc.
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500(R) Company and a member of the NASDAQ 100(R) Index, Henry Schein employs nearly 16,000 Team Schein Members and serves more than 775,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record $8.9 billion in 2012, and have grown at a compound annual rate of 17% since Henry Schein became a public company in 1995. For more information, visit the Henry Schein Web site at www.henryschein.com.

Cautionary Note Regarding Forward-Looking Statements
In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend, " "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

18 october
BioHorizons Asia Pacific Symposium Series 2013

BIRMINGHAM, AL, October 18, 2013

Experts in dental implantology and its related specialties came together on September 6-8, 2013 at the prestigious Palladium Hotel in Mumbai, India for the BioHorizons Asia Pacific Symposium, hosted by BioHorizons and its local authorized distributor, Katara Dental Pvt. Ltd.

The program, developed by Dr. Mukesh Katara, Managing Director of Katara Dental in cooperation with BioHorizons, included two sold out pre-congresses conducted by Drs. Bach Le, Udatta Kher and Ali Tunkiwala, and two days of clinical presentations led by internationally recognized opinion leaders. The scientific program addressed topics such as immediate placement and loading, implant complications, treatment planning and tissue regeneration and featured clinical case review and practical techniques for implant dentistry. "I believe that the program was highly informative and educational," said Dr. Srinath Thakur, Principal, SDM Dental College, Dharwad, India. "Such programs are the need of the hour for dentists practicing implantology. I look forward to many more similar programs in the future."

Mr. Mark Neri, Vice President of International Sales for BioHorizons, stated, "We are proud to have hosted a Symposium in India for the first time. The internationally renowned group of speakers presented exciting advances in dental implantology and provided an opportunity for our attendees to continue learning ways to restore smiles through innovation."

According to Veronica Zamora, Manager of International Marketing & Education for BioHorizons, "India is one of the world's finest business destinations and Mumbai, in particular, offered us a magnificent experience when conducting such an important educational event. Our next destination will be Dubai and we plan to host many clinicians from the Asia Pacific region for this symposium, which is scheduled for May 7-9, 2014."

About BioHorizons - BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons proprietary Laser-Lok® microchannel surface technology. With 25 years of research and 35 published studies or articles, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long term crestal bone maintenance. The BioHorizons portfolio is offered in 85 markets around the world. For more information, visit biohorizons.com.

Contacts

BioHorizons
Veronica Zamora, 205-986-7927
Manager, International Marketing & Education

22 may
BioHorizons Global Symposium 2013 Spotlights Solutions to Dental Implant Controversies

BIRMINGHAM, AL, May 22, 2013 / BUSINESS WIRE / --

The 2013 BioHorizons Global Symposium brought together over 1,400 dental professionals from 55 countries to the prestigious Fontainebleau Hotel in Miami, Florida. Thirty-eight clinicians presented throughout a three day program on April 25-27 that featured concurrent surgical and restorative tracks, hands-on training and faculty-moderated discussion panels.

The program was led by internationally-recognized opinion leaders who addressed a range of topics including immediate placement and loading, implant complications, treatment planning and tissue regeneration. Pre-symposium courses included topic-specific breakout sessions and a dedicated Spanish language Symposium by key thought leaders from throughout Latin America. "This is the most impressive, educational implant forum I have ever attended," said Dr. Daniel Spagnoli, Chair of Oral & Maxillofacial Surgery, LSU School of Dentistry.

R. Steven Boggan, President and CEO of BioHorizons, stated "This was the most comprehensive agenda in our history. The Global Symposium incorporated research and practical perspectives from top clinicians around the world. They described the latest technologies and techniques for resolving challenging issues within implant dentistry. With technology evolving so rapidly, it's important that clinicians base their decisions on evidence-based solutions, not industry rhetoric. The Global Symposium met that important need based on the overwhelmingly positive feedback from all of the attendees."

"Given the tremendous response, we will continue to offer these much needed programs to dental clinicians," said Greg Bryant, Director of Continuing Education. "The next three stops in our International Symposium Series have already been scheduled for Mumbai, India (2013), Dubai (2014) and Los Angeles (2015)."

For more information, visit www.biohorizons.com.

BioHorizons Global Symposium 2013 Faculty

Dr. Edward P. Allen
Dr. Orlando Alvarez
Dr. Arturo Bilbao
Dr. Lyndon Cooper
Dr. Lewis Cummings
Dr. Abdelsalam Elaskary
Dr. David Garber
Dr. Pedro Gazzotti
Dr. Nico Geurs
Dr. Gerhard Iglhaut
Dr. Julian Jaramillo
Dr. Bach Le
Dr. Sonia Leziy
Dr. Tomas Linkevicius
Dr. Kenneth Malament
Dr. Brahm Miller
Dr. Carl Misch
Dr. Craig Misch
Dr. Justin Moody
Dr. Rodrigo Neiva
Dr. Myron Nevins
Dr. Arthur Novaes
Dr. Michael Pikos
Dr. Jay Reznick
Dr. Jack Ricci
Dr. Alain Romanos
Dr. John Russo
Dr. Maurice Salama
Dr. Guido Samachiaro
Dr. Hamid Shafie
Dr. Cary Shapoff
Dr. Daniel Spagnoli
Dr. Marius Steigmann
Dr. Miguel Troiano
Dr. David Troncoso
Dr. Frank Tuminelli
Dr. Hom-Lay Wang
Dr. Natalie Wong

About BioHorizons - BioHorizons is a leader in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons proprietary Laser-Lok® microchannel surface technology. With 25 years of research and 35 published studies or articles, Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long term crestal bone maintenance. The BioHorizons portfolio is offered in 85 markets around the world. For more information, visit biohorizons.com.

Contacts

BioHorizons
Greg Bryant, 205-986-7894
Director, Communication & Education
2012 press releases
14 august
BioHorizons launches MinerOss® Cancellous providing dental implant professionals a wide
variety of bone grafting solutions

BIRMINGHAM, AL, August 14, 2012 / BUSINESS WIRE / --

BioHorizons, a dental implant company, announces the launch of MinerOss® Cancellous, a mineralized cancellous bone allograft for periodontal defects, extraction sockets, grafting for implant placement, and ridge and sinus augmentation. The addition of MinerOss Cancellous increases the number of bone grafting options in the MinerOss family, offering clinicians a variety of solutions.

"MinerOss Cancellous is an outstanding choice for particulate grafting," said Dr. Bach Le, DDS, MD, FICD, FACD, Los Angeles, CA. "Its exceptional handling and predictable results have proven to be an asset in my practice."

The cancellous allograft ranges in size from 300 to 1,000 microns providing ideal handling characteristics for a wide variety of regenerative procedures. MinerOss Cancellous is readily available in 0.5cc, 1.0cc, and 2.5cc easy-to-use vials with a screw-top lid. The osteoconductive properties along with the fast remodeling time of MinerOss Cancellous promote rapid revascularization and predictable results.

"With the addition of MinerOss Cancellous to the BioHorizons portfolio, dental implant professionals now have a variety of biologic choices to suit the clinical requirements for their patients," said Steve Boggan, President and CEO of BioHorizons.

About BioHorizons - BioHorizons, Inc. is a fast growing implant and biologics company in the dental implant industry. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions for the replacement of missing teeth. BioHorizons products are available in 85 markets around the world. For more information, visit www.biohorizons.com.

7 february
BioHorizons Unveils New Mobile Application for Dental Implant Professionals

BIRMINGHAM, AL, February 7, 2012 / BUSINESS WIRE /--

BioHorizons, a dental implant company, today announced a new mobile application allowing Apple iPad mobile digital device users access to the latest BioHorizons product information. The free app is designed to conveniently provide dental clinicians with relevant videos and literature in a single location.

"We are proud to introduce an iPad application developed to provide up-to-date, relevant information about our products," said Todd Strong, Chief Operating Officer of BioHorizons.

With the new BioHorizons app, dental implant professionals have the ability to easily share educational materials with their patients. Users can also reference surgical manuals and technique guides for the many BioHorizons implant systems.

The BioHorizons app provides convenient access to a database of relevant clinical studies and videos on various dental implant topics. This tool also allows dental clinicians quick access to product, company and contact information.

"Our new app gives dental professionals quick, accessible information for placing and restoring BioHorizons implants on the most widely accepted digital platform. We continue to provide our customers advanced technologies that help them to excel in their practice," Strong said.

BioHorizons literature and videos are optimized for the iPad and conveniently available offline. Automatic updates occur anytime a Wi-Fi connection is available.

This user-friendly app is free and filled with features. It can be downloaded from a link on the BioHorizons website www.biohorizons.com. or on the iTunes store.

About BioHorizons
BioHorizons, Inc. is a fast growing implant and biologics company in the dental implant industry. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions for the replacement of missing teeth. BioHorizons products are available in 85 markets around the world. For more information, visit www.biohorizons.com.

Apple, iTunes and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.

Contacts
BioHorizons, Inc.
Todd Strong, 205-967-7880
Chief Operating Officer


2011 press releases
9 july
BioHorizons, a Leading Dental Implant Manufacturer, Announces $50 Million Credit Facility

BIRMINGHAM, AL, July 29, 2011 / BUSINESS WIRE / --

Proceeds Used for Debt Repayment and General Corporate Purposes

BioHorizons, Inc. today announced that it has closed on a five year $50 million subordinated secured credit facility provided by funds affiliated with Deerfield Management and Piper Jaffray & Co. Proceeds will be used to fully repay an outstanding convertible note held by HealthpointCapital Partners II, LP and for general corporate purposes.

Deerfield Management is a leading healthcare investment organization. Piper Jaffray & Co. served as exclusive private placement agent to BioHorizons on this transaction.

About BioHorizons
BioHorizons, Inc. is a fast growing implant and biologics company in the dental implant industry. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions for the replacement of missing teeth. BioHorizons products are available in 85 markets around the world. For more information, visit www.biohorizons.com.

Contacts
BioHorizons, Inc.
David Wall, 205-986-1234
Chief Financial Officer
investorrelations@biohorizons.com


26 july
Robert H. Blankemeyer Joins Board of Directors for BioHorizons, a Leading Dental Implant Manufacturer

BIRMINGHAM, AL, July 26, 2011 / BUSINESS WIRE / --

BioHorizons, Inc., a medical device company that designs, develops, manufactures and markets a broad and comprehensive line of innovative, proprietary and evidence-based dental implants, as well as hard and soft tissue regeneration products for the replacement of missing teeth, announced today that Robert H. Blankemeyer has been elected to the BioHorizons Board of Directors.

Mr. Blankemeyer is an accomplished medical device industry executive. For the last 11 years, he was employed at Medtronic, Inc. where he was Senior Vice President and President of the Surgical Technologies sector. He also served on the Medtronic executive committee, operating committee and venture board and corporate management incentive plan committee.

Prior to joining Medtronic, Mr. Blankemeyer spent 22 years in the field of ophthalmology with Storz Ophthalmics having held senior positions in global sales and marketing management, as well as chief operating officer and president. Storz was a subsidiary of American Home Products and American Cyanamid, where he was a member of the Presidents Council.

Mortimer (Tim) Berkowitz III, Chairman of BioHorizons, said "We are delighted to welcome Bob to the Board of BioHorizons. Bob is a highly respected leader with a remarkable track record of success in the medical device industry and we look forward to adding his operating experience and strategic vision to our Board."

Steve Boggan, the Company's President and Chief Executive Officer, stated "I am excited to have the opportunity to work with Bob and receive the benefit of his deep experience in the medical device industry."

Contacts
BioHorizons, Inc.
David Wall, 205-986-1234
Chief Financial Officer
investorrelations@biohorizons.com


2010 press releases
24 june
BioHorizons, Inc. Files Registration Statement for Initial Public Offering of Common Stock

BIRMINGHAM, AL-- June 24, 2010 / Marketwire / --

BioHorizons, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

Piper Jaffray & Co. and Jefferies & Company, Inc. will act as joint book-running managers of the offering. Canaccord Genuity and Cowen and Company will act as co-managers for the offering. The offering will be made only by means of a prospectus.

Copies of the preliminary prospectus, when available, may be obtained by contacting Piper Jaffray & Co., Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN, 55402 (telephone: 800-747-3924/email: prospectus@pjc.com) or Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 (telephone: 877-547-6340/email: Prospectus_Department@Jefferies.com)

About BioHorizons, Inc.
BioHorizons, Inc. is a medical technology company focused on developing, manufacturing and marketing a broad and comprehensive line of innovative, proprietary and evidence-based dental implants, as well as hard and soft tissue regeneration products, for the replacement of missing teeth.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Contact Information
For more information:
David A. Wall
Chief Financial Officer
BioHorizons, Inc.
(205) 967-7880
Email Contact

Lynn C. Pieper
Westwicke Partners
(415) 202-5678
Email Contact


7 april
New Study Shows Dental Patients Experience Long Term Benefits from BioHorizons Dental Implants

BIRMINGHAM, AL, April 7. 2010 / BUSINESS WIRE / --

BioHorizons, a leading manufacturer of dental implants and tissue regeneration products, reported today that a recently published study demonstrates that dentists who use Laser-Lok® dental implants to replace missing teeth can give patients years of normal dental function and appearance.

"This study is consistent with the results I have had for the last 10 years with Laser-Lok dental implants," said Dr. Cary Shapoff, a periodontist in Fairfield, CT and the lead author of the study. "These implants have shown an exceptional ability to maintain patients' dental health and esthetics over the long term."

Here are the study details:

  • Forty-one patients with missing teeth were treated with Laser-Lok dental implants.
  • Patients were missing one or more teeth due to genetics, trauma, hygiene or a failed endodontic procedure (commonly known as a root canal).
  • After three years, these patients had a 98% success rate with minimal bone loss (0.46mm).
  • The complete study is available in the April issue of The International Journal of Periodontics & Restorative Dentistry (IJPRD)1.


"While dental implants, in general, have a very high success rate, dentists often accept that patients will experience 2mm of bone loss over the life of an implant," commented Dr. Shapoff. "This bone loss can result in an unnatural looking smile. BioHorizons implants have shown a unique ability to stop this bone loss, allowing patients to maintain a natural, esthetic smile."

BioHorizons Laser-Lok dental implants are a proprietary design that causes the bone and soft tissue to attach and be retained around the dental implant. It is the only surface cleared by the FDA that establishes a physical, connective tissue attachment (unlike Sharpey fiber attachment).

"Stable soft tissue attachment to Laser-Lok dental implants, resulting in a biologic seal, was documented for the very first time in studies published in 20082,3," commented Dr. John L. Ricci, PhD, Associate Professor, Department of Biomaterials and Biomimetics at NYU College of Dentistry. "This latest study definitively confirms that the clinical benefits of a stable soft tissue envelope around Laser-Lok dental implants are significant when compared to the typical 1.5-2mm of bone loss documented with other implant systems."

Steve Boggan, President and CEO of BioHorizons, added, "The majority of our customers have converted to Laser-Lok dental implants because of the benefits they have seen for their patients. This study further validates their clinical experience. We look forward to the release of additional studies later this year comparing BioHorizons implants to dental implant systems from other companies."

About BioHorizons, Inc.
BioHorizons a fast growing implant and biologics companies in the dental implant industry. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions to treat missing teeth. BioHorizons products are available in over 70 countries around the world. For more information, visit www.biohorizons.com.

Contacts
BioHorizons, Inc.
Boyd Peters, Director of Implant Marketing
205-986-7903
bpeters@biohorizons.com



  1. Radiographic Analysis of Crestal Bone Levels on Laser-Lok® Collar Dental Implants. C Shapoff, B Lahey, P Wasserlauf, D Kim. IJPRD, Vol 30, Number 2, 2010
  2. Human Histologic Evidence of a Connective Tissue Attachment to a Dental Implant. M Nevins, ML Nevins, M Camelo, JL Boyesen, DM Kim. IJPRD. Vol. 28, No. 2, 2008.
  3. The Effects of Laser Microtextured Collars Upon Crestal Bone Levels of Dental Implants. S Weiner, J Simon, DS Ehrenberg, B Zweig, and JL Ricci. Implant Dentistry, Volume 17, Number 2, 2008. p. 217-228.

2009 press releases
27 may
BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok® Microchannels

BIRMINGHAM, AL, May 27, 2009 / PRNewswire / --

Clinicians from 36 countries interact with internationally recognized thought leaders

Dentists from 36 countries convened at the BioHorizons 2009 Global Symposium to learn about the latest technologies impacting implant dentistry. The theme of this year's meeting was "Integrating technology for the continuum of care" focusing on recent advances in digital dentistry, treatment planning, implant surfaces, tissue regeneration and implant-specific restorations.

The scientific sessions were led by top dental clinicians such as Drs. Carl E. Misch, Michael A. Pikos, Maurice Salama, Edward P. Allen, David Garber and Scott Ganz who provided insight into today's most challenging implant and regeneration topics.

R. Steven Boggan, President and CEO, stated "Given the current economic climate and the struggles our competitors are experiencing, we are especially proud of the quality and participation of our 10th Annual Symposium. It is a testament to the education the panel of assembled clinicians provides and the relevance of the topics and technologies discussed."

Highlights of the three day meeting included the Spanish language forum, the numerous hands-on training sessions and the clinician-moderated panel discussions. Attendees enjoyed asking questions to the featured presenters or using PDA's to send their questions electronically to the session moderators.

The key product topics this year included the introduction of VIP2.1 treatment planning software, shown to be intuitive and user-friendly, and the latest clinical results from Laser-Lok microchannels. "Laser-Lok was the stand out technology this year," said Clark Barousse, Senior VP, Global Sales & Marketing, "as presenters consistently showed results unique to other implant systems. It was exciting to hear industry thought leaders universally conclude they are getting better clinical results by using Laser-Lok." This year's case abstract competition winner, Spyros Botos, DDS, MSD of Greece, showed with his controlled overdenture study that Laser-Lok dental implants achieved superior bone maintenance and reduced probing depth when compared to Nobel Replace™ Select.

Symposium presenters and moderators included Drs. Carl E. Misch, Maurice Salama, Michael A. Pikos, Scott Ganz, Edward P. Allen, David Garber, Jack Ricci, Natalie Wong, Ray Yukna, Michael Reddy, Hamid Shafie, Jay Malmquist, Michael Klein and Murray Arlin.

About BioHorizons Implant Systems, Inc.
BioHorizons was founded in 1994 based on technology developed at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com


19 may
BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok® Microchannels

BIRMINGHAM, AL, May 19, 2009

3-Year Study Highlights the Clinical Success of Dental Implants with Laser-Lok Technology over Traditional Implants

BioHorizons, a leader in the dental implant industry, reported today that data from a three-year prospective, controlled, multi-center study of implants with Laser-Lok surface treatment confirmed previous results observed for Laser-Lok in vitro and in animal studies. Laser-Lok implants showed superior crestal bone maintenance when compared to traditional implants and to bone loss commonly reported in other studies.

"A physical, connective tissue attachment to dental implants was shown for the first time in human and animal studies on Laser-Lok published last year," commented Dr. John L. Ricci, PhD. "This latest study shows the clinical benefits of a physical connective tissue attachment to Laser-Lok are significant when compared to the typical 1.5-2mm of bone loss documented with other implants."

The study, published in Implant Dentistry, followed 20 pairs of implants in 15 patients from 1 to 37 months postoperative. A dental implant with Laser-Lok surface treatment was placed adjacent to a control implant of the same body design without Laser-Lok. Measurement values were reported for bleeding index, plaque index, probing depth, and crestal bone loss.

At 37 months, the mean probing depth was 3.60mm and the mean crestal bone loss was 1.94mm for the control implants versus only 2.30mm and 0.59mm, respectively, for the Laser-Lok implants. The difference in probing depth across the patient population demonstrated the consistent formation of a stable soft-tissue seal around the Laser-Lok implants and above the crestal bone. In addition, no difference in bleeding or plaque index between the Laser-Lok implants and the machined implants was shown, alleviating possible concerns about placing Laser-Lok implants supracrestal.

Steve Boggan, President and CEO of BioHorizons, added, "This study provides valuable information about the positive, long-term outcomes of dental implants with Laser-Lok microchannels and confirms what our customers have been telling us for some time."

The effectiveness of Laser-Lok has been shown in over 15 years of in vitro, animal, and human studies at leading universities. This patented precision laser surface treatment is unique within the industry as the only surface treatment shown to attract a physical connective tissue attachment to a predetermined zone on the implant while inhibiting epithelial downgrowth and preserving the coronal level of bone over the long term.

About BioHorizons Implant Systems, Inc.
BioHorizons was founded in 1994 based on technology developed at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com


  1. Human Histologic Evidence of a Connective Tissue Attachment to a Dental Implant. M Nevins, ML Nevins, M Camelo, JL Boyesen, DM Kim. The International Journal of Periodontics & Restorative Dentistry. Vol. 28, No. 2, 2008.
  2. The Effects of Laser Microtextured Collars Upon Crestal Bone Levels of Dental Implants. S Weiner, J Simon, DS Ehrenberg, B Zweig, and JL Ricci. Implant Dentistry, Volume 17, Number 2, 2008. p. 217-228.
  3. Clinical Evaluation of Laser Microtexturing for Soft Tissue and Bone Attachment to Dental Implants. G. E. Pecora, R. Ceccarelli, M. Bonelli, H. Alexander, J.L. Ricci. Implant Dentistry: Vol. 18, No. 1, February 2009, pp 57-66.
  4. Clinical References available.

24 march
BioHorizons Announces its 2009 Global Symposium: Bringing Together Top Thought Leaders in the Dental Implant Industry to Provide Insight on Integrating Technology into the Continuum of Care

BIRMINGHAM, AL, March 24, 2009 / PRNewswire / --

BioHorizons announces today that its 2009 Global Symposium will take place Thursday, April 30, to Saturday, May 2, at the Hilton Chicago. This educational event will focus on recent advances in digital dentistry, treatment planning, implant surface treatments, tissue regeneration and implant specific restorations.

Scientific sessions will bring together the outstanding and diverse expertise of top dental clinicians such as Drs. Carl E. Misch, Michael A. Pikos, Maurice Salama, Edward P. Allen, and Scott Ganz to provide insight into today's most challenging implant and regeneration topics, including technical advances in diagnostic three-dimensional imaging and treatment planning software. Each clinician-moderated session will feature a panel discussion of audience-submitted questions that fosters a highly interactive learning environment. The three days of continuing education will include hands-on training sessions and dedicated educational tracks for auxiliary and office staff.

Presenters and moderators include Drs. Carl E. Misch, Maurice Salama, Michael A. Pikos, Scott Ganz, Edward P. Allen, David Garber, Jack Ricci, Natalie Wong, Ray Yukna, Michael Reddy, Hamid Shafie, Jay Malmquist, Michael Klein, and Murray Arlin.

BioHorizons is a fast growing dental implant company because of unique offerings like Laser-Lok® microchannels, VIP 2.1 treatment planning software and gold-hued esthetic abutments provided with every bone level implant system. Symposium presentations will illustrate the unique position of BioHorizons to assist dental clinicians throughout the continuum of care.

"Each year, the BioHorizons Global Symposium stimulates invaluable interaction within the dental implant community," said Steve Boggan, BioHorizons President & CEO. "In the current global economic climate, it is important to develop advanced knowledge and strong relationships to achieve superior esthetic results for patients and generate new opportunities for dental practices."

To register and view schedules, detailed session topics and hotel information, go to www.biohorizons.com, or call (866) 872-9785. Register early, attendance will be limited to maintain an environment conducive to learning. This event will offer up to 20 CE credit hours.

About BioHorizons Implant Systems, Inc.
BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including dental implants, surgical planning software, regenerative products, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com


2008 press releases
15 december
BioHorizons launches a new customer-focused website

BIRMINGHAM, AL, December 15, 2008 / PRNewswire / --

Birmingham, Alabama, December 15, 2008 - BioHorizons, a leading oral reconstructive device company known for proprietary implant designs and regeneration products, announces the introduction of a new customer-focused, interactive website. The site, www.biohorizons.com, reflects the company's current branding and offers visitors a valuable on-line experience with useful and easily accessible information. The new graphics-based, On-line Catalog allows customers to view detailed product specifications and account history, place orders 24/7, and track shipments.

BioHorizons COO, Todd Strong, says: "At BioHorizons, we have always taken customer care very seriously, talking and listening to our customers and taking their views into account. Our new website design is the latest example of our commitment."

BioHorizons is at the forefront of digital dentistry and sets itself apart from the competition with science-based research, innovative products, and the highest level of service. The new website "sets the trend" by being highly graphics-based, interactive, user-friendly and secure.

BioHorizons President and CEO, Steve Boggan, added, "During these trying economic times, BioHorizons remains dedicated to science, innovation, and service while striving to reduce the overall costs of placing and restoring implants. Customers can rest assured they are receiving the highest quality products backed by some of the strongest scientific research in the industry, but at consistently reasonable prices. The launch of our new website with enhanced On-line Catalog and cost-saving bundling of our implants with abutments and prosthetics with lab components are key examples of our focus on meeting customers' needs."

About BioHorizons Implant Systems, Inc.
BioHorizons was founded in 1994 based on technology developed at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com


23 june
BioHorizons Global Symposium 2008 Combines Record Attendance With Groundbreaking Technology

BIRMINGHAM, AL, June 23, 2008 / PRNewswire / --

Birmingham, Alabama, June 23, 2008 - The 2008 BioHorizons Global Symposium drew more than 1,000 people from 42 countries to San Diego, California for a 3-day scientific program on today's most important implant and tissue regeneration topics. Each clinician-moderated session featured a panel discussion of audience-submitted questions that kept participants fully engaged in the program.

Members of the scientific panel and moderators included Drs. Carl E. Misch, Michael A. Pikos, Maurice Salama and Michael Reddy. Featured presenters included Drs. Edward P. Allen, Stuart Froum, Michael McCracken, Craig Misch, Myron Nevins, and Marius Steigmann.

The keynote session featured presentations on the ground-breaking Laser-Lok® microchannels, BioHorizons' proprietary surface treatment now offered on Tapered Internal, Single-stage and Internal implants. Dr. Jack Ricci from NYU presented 15 years of in vitro, animal and human studies conducted at leading universities around the world on this precision-engineered surface. Dr. Myron Nevins from Harvard University presented results from his landmark study: Human Histological Evidence of a Connective Tissue Attachment to a Dental Implant.* In this study, Laser-Lok was shown to attract a physical connective tissue attachment to a predetermined zone on the implant while inhibiting epithelial downgrowth and preserving coronal bone levels. Dr. Nevins also showed Laser-Lok implants placed up to 9-years post-op with little to no bone loss.

BioHorizons and Dental Technologies, Inc. (DTI) also announced a new Restoration-to-Implant Lifetime Warranty covering implants, abutments and restorations when fabricated by a participating DTI Laboratory. This unique offer, made possible by the recent merger of BioHorizons and DTI, brings incredible value and practice building potential to the entire implant team.

R. Steven Boggan, President and CEO, said in regard to the unprecedented attendance: "BioHorizons continues to be a fast growing dental implant company because of unique offerings like Laser-Lok and our Lifetime Warranty program. The Global Symposium presentations and attendance are indicative of our growing momentum that stems from science-based design and synergies with high-tech partners such as DTI."

BioHorizons will present the 2009 Global Symposium from April 30 to May 2, 2009, in Chicago, Illinois. Attendance will be limited, and another sell-out is expected, so please register early to ensure your spot.

*International Journal of Periodontics & Restorative Dentistry, Vol. 28, No.2, April 2008.

About BioHorizons Implant Systems, Inc.
BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including surgical planning software, regenerative products, dental implants, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com


5 may
Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market

EATONTOWN, NJ, May 5, 2008 / PRNewswire-FirstCall / --

Osteotech, Inc. (Nasdaq: OSTE - News), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has signed an exclusive distribution agreement with BioHorizons, Inc., effective as of April 1, 2008, under which BioHorizons will market Osteotech's bone regeneration products to the dental market in 29 countries in Europe, the Middle East, Latin America and Asia. Osteotech and BioHorizons previously entered into an agreement for BioHorizons to distribute Osteotech's products to the United States dental market in 2000.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "Our domestic relationship with BioHorizons has been very successful and we are pleased to be able to expand this relationship overseas. We believe our bone regeneration products are the perfect solution for the new bone grafting procedures being developed to replace missing or extracted teeth with dental implants or as support for dentures, crowns and bridges."

About BioHorizons Implant Systems, Inc.
BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including surgical planning software, regenerative products, dental implants, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com

About Osteotech, Inc.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 30, 2008 and the Company does not intend to update this information.


15 april
BioHorizons Announces the Purchase of Implant Logic Systems

EATONTOWN, NJ, April 15, 2008 / PRNewswire-FirstCall / --

BioHorizons, Inc.("BioHorizons") announced today the completion of its purchase of Implant Logic Systems, Ltd. ("ILS"), first announced on January 30, 2008. Implant Logic Systems will operate as a subsidiary of BioHorizons. Steve Boggan, CEO of BioHorizons, commented, "We are excited to expand our product offering to include VIP Virtual Implant Placement planning software and CAD/CAM surgical guides. This acquisition is a key milestone for us as we move the field of implant dentistry into the digital age."

For More Information:
Steve Boggan
President and CEO of BioHorizons
205.967.7880

About BioHorizons Implant Systems, Inc.
BioHorizons was founded in 1994 based on technology developed at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com

About Implant Logic Systems
Implant Logic Systems is leading the dental implant market with innovative, technologically advanced, surgical tools which significantly improve implant placement quality and accessibility for both doctors and patients. Implant Logic Systems operates in the fields of software technology and medical devices to create a revolutionary implant placement technique. This technique is intended to be less invasive to the patient, shorten recovery time, reduce surgery time by up to 75%, and provide a more accurate implant placement. Implant Logic Systems has experienced rapid growth over the past several years. Implant Logic Systems' computer guided system has proven itself in thousands of clinical surgeries.


21 february
BioHorizons, Inc. Announces its Merger with DTI Dental Technologies, Inc.

BIRMINGHAM, AL, and DUBLIN, CA February 21, 2008 / PRNewswire / --

BioHorizons, Inc. ("BioHorizons" or the "Company") has been formed to create a leading digital dentistry company in the dental implant market by combining DTI Dental Technologies, Inc. and BioHorizons Implant Systems. The uniqueness stems from expertise in the digital world provided by a large scale dental laboratory and the implant expertise provided by a leading dental implant company.

Digital dentistry is the future of implant dentistry. The sophisticated dental laboratory has almost all of the experience and knowledge of digital data gathering, computer aided design of crowns and abutments, and computer aided manufacturing. Today, virtually no dental implant company has knowledge of or experience with digital technology or its use. Long term, leadership and success in the dental implant industry will go to early adopters who can execute, support, and deliver to dentists a digitally designed and manufactured, complete and customized set of products and tools for each patient procedure. BioHorizons, Inc. will be the first dental implant company in the age of digital dentistry.

BioHorizons' headquarters will be in Birmingham, Alabama. The combined company generated approximately $150 million in revenues in 2007, making it one of the largest implant dentistry companies in the world. The Company will have 23 operating facilities in North America, eight international facilities and over 1,000 employees. Most importantly, this marriage creates a differentiated restorative dental company that has the most complete product offering in the industry. This provides BioHorizons the ability to streamline the implant and restorative process creating a more efficient continuum of care and superior patient outcomes.

"This development creates a leader in restorative and implant dentistry" stated R. Steven Boggan, President and CEO of BioHorizons. "We are confident that we can decrease treatment times while simultaneously improving patient outcomes. Being the only company with direct experience from surgical planning through final restoration, we offer our current and future customers superior service."

Wallace Sholdice, President of DTI explained, "We are very excited about this combination. BioHorizons and DTI share a vision for how to move the practice of dentistry into the digital age, especially implant dentistry. We will have the resources and expertise to provide significant value to our customers, particularly through continuing education and marketing programs that only an integrated company like BioHorizons can offer."

Canaccord Adams acted as financial advisor in the merger.

For More Information:
Steve Boggan
President and CEO of BioHorizons
205.967.7880

About BioHorizons Implant Systems, Inc.
BioHorizons was founded in 1994 based on technology developed at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.
www.biohorizons.com

About DTI
DTI is the only dental laboratory network that provides innovative full practice growth support to dentists who want to excel above the status quo. The Company is a leader in digital dentistry which includes CAD/CAM restorations. Strategically located throughout North America, DTI's laboratory network extends beyond a simple dental laboratory support as each laboratory represents an epicenter of innovation and artistry for the benefit of each practice we serve. www.dtidental.com


30 january
BioHorizons Announces Agreement to Purchase Implant Logic Systems

BIRMINGHAM, AL, and Cedarhurst, NY, January 30, 2008 / PRNewswire / --

BioHorizons Implant Systems, Inc. announced today its parent company has entered into a definitive agreement to purchase Implant Logic Systems, Ltd. ("ILS"). ILS is a leading innovator and provider of technology solutions for the implant dentistry market. ILS's Virtual Implant Placement software enables implantologists to view CT scans and create virtual implant treatment plans. Implantologists can then use ILS's Compu-Guide system to create custom milled surgical guides that bring the virtual treatment plan into the operating suite. Terms of the transaction were not disclosed.

"We are thrilled to add the technology and expertise of ILS to BioHorizons," stated R. Steven Boggan, President and CEO of BioHorizons. "Our customers have expressed great interest in computer assisted implant treatment planning software and surgical guides. ILS perfectly addresses this customer need. In addition, the Compu-Guide surgical guide system is designed to allow the clinician to place implants more accurately, more quickly and more safely than is otherwise possible. The acquisition of ILS will create significant value for our customers."

Dr. Michael Klein, President and CEO of ILS, stated, "We are excited about the opportunity to join with BioHorizons. ILS is already well known for its implant planning software and innovative computer guided surgical tools, but our customers will now get the expanded benefits of working with BioHorizons, one of the most progressive and customer-centric companies in the industry."

For More Information:
Steve Boggan
President and CEO of BioHorizons
205.967.7880

About Implant Logic Systems
Implant Logic Systems is leading the dental implant market with innovative, technologically advanced, surgical tools which significantly improve implant placement quality and accessibility for both doctors and patients. Implant Logic Systems operates in the fields of software technology and medical devices to create a revolutionary implant placement technique. This technique is intended to be less invasive to the patient, shorten recovery time, reduce surgery time by up to 75%, and provide a more accurate implant placement. Implant Logic Systems has experienced rapid growth over the past several years. Implant Logic Systems' computer guided system has proven itself in thousands of clinical surgeries.


About BioHorizons
BioHorizons was founded in 1994 as an incubator company at the University of Alabama at Birmingham. The company has a broad product offering of dental implants including Tapered Internal, Single-stage, Internal, External, One-piece 3.0, and Overdenture. BioHorizons has exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors. The Company was purchased by HealthpointCapital in 2006.
www.biohorizons.com


2007 press releases
9 december
BioHorizons Expands to New 44,000 Square Foot Facility

BIRMINGHAM, AL, Dec. 9, 2007 / PRNewswire / --

BioHorizons Implant Systems, Inc. relocated its global headquarters in Birmingham, Alabama, to a state-of-the-art, 44,000 square foot facility. The new facility, located at 2300 Riverchase Center, houses all administrative services, a newly formed manufacturing facility and a distribution center. The manufacturing facility will include machining, surface treatment and packaging services.

The new facility was required due to tremendous growth and an expanding product offering. BioHorizons' President and CEO Steve Boggan commented, "We have experienced significant revenue growth and are excited about our future prospects. As a result, a new facility was required to house our expanding administrative and operations team. Further, the expanded facility allows for vertical integration of our product line to realize margin improvement and manufacturing efficiencies." He continued by stating, "Having manufacturing in-house will also allow us to be even more responsive to the needs of our customers."

About BioHorizons
BioHorizons was founded in 1994 as an incubator company at the University of Alabama at Birmingham. BioHorizons' flagship External Implant System, a proprietary system of dental implants and related products, was launched in 1997. BioHorizons has a strong product offering of dental implants including internal hex, external hex, straight-walled, tapered, overdenture and one-piece implants. BioHorizons has signed exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain and United Kingdom. Products are distributed in the rest of the world via a network of independent distributors. The Company was purchased by HealthpointCapital in 2006.
www.biohorizons.com

About HealthPointCapital
HealthpointCapital is a values-driven, research-based private equity firm exclusively focused on the musculoskeletal sector- specifically orthopedics and dental. With a cumulative 85 years of experience in healthcare technology, research and private investing, HealthpointCapital helps clients capitalize on the explosive growth and unique investment opportunities in one of the fastest growing sectors of the medical device industry.

HealthpointCapital manages $650 million of institutional capital.
www.healthpointcapital.com


15 november
BioHorizons Introduces Its New Tapered Internal Implants Featuring Laser-Lok® Microgrooves

BIRMINGHAM, AL, November 15, 2007 / PRNewswire / --

BioHorizons Implant Systems, Inc. has introduced a new line of Tapered Internal Implants that feature a unique thread design and proven surface engineering technology. This product introduction is the first from BioHorizons to address the tapered market segment which accounts for over 50% of the U.S. dental implant market.

The Tapered Internal Implants incorporate the Laser-Lok precision laser collar surface treatment, which controls cellular growth and directs hard and soft tissue attachment onto dental implants. The result of over 15 years of evidence-based research and documented research studies, the proprietary 8 and 12 micron Laser-Lok channels play a vital role in inhibiting epithelial downgrowth and attaching and retaining crestal bone. The implant design and surface treatment displayed improved hard and soft tissue response leading to excellent esthetic results in animal and human research studies.

"These new implants will offer supreme esthetic and clinical results to our global dental implant customers," commented Steve Boggan, President and CEO of BioHorizons. "Building on BioHorizons' commitment to science, innovation and service, we are pleased to bring such a novel product to the dental implant industry."

Contacts
BioHorizons, Inc.
Steve Boggan, President and CEO of BioHorizons
205-967-7880

About BioHorizons
BioHorizons was founded in 1994 as an incubator company at the University of Alabama at Birmingham. BioHorizon's flagship External Implant System, a proprietary system of dental implants and related products, was launched in 1997. The Company was purchased by HealthpointCapital in 2006. BioHorizons has a strong product offering of dental implants including internal hex, external hex, overdenture and one-piece implants. BioHorizons has signed exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The company has a direct sales force in the U.S., Canada, Germany, Spain and United Kingdom. Products are distributed in the rest of the world via a network of independent distributors.


2006 Press Releases
22 august
HealthPointCapital announces the purchase of BioHorizons Implant Systems Inc.

NEW YORK, NY, and BIRMINGHAM, AL, August 22, 2006 / PRNewswire / --

HEALTHPOINTCAPITAL, LLC ("HEALTHPOINTCAPITAL") announced today the purchase of BioHorizons Implant Systems, Inc. ("BioHorizons" or "Company"). BioHorizons designs, produces and distributes oral reconstructive devices including dental implants and tissue regeneration products. BioHorizons, located in Birmingham, Alabama, is a fast growing company in the dental industry. Terms of the transaction were not disclosed.

"The dental implant market represents one of the fastest growing sectors in the medical technology industry," stated Mortimer Berkowitz III, President and Managing Director of HEALTHPOINTCAPITAL. "Dental implants offer patients superior clinical outcomes and improved esthetics compared to traditional treatments such as bridges and dentures. BioHorizons has a legacy of providing superior product quality and unmatched clinical service."

Steve Boggan, President and CEO of BioHorizons, commented that, "We are extremely pleased with the outcome for our shareholders, employees and customers. Our management team is excited about the opportunity to partner with HEALTHPOINTCAPITAL and expand our growth prospects in this attractive market."

Mr. Berkowitz becomes the Chairman of the Board and Mr. Boggan will continue as President, Chief Executive Officer and Director of the Company. BioHorizons plans to expand its headquarters in Birmingham and the management team will remain important shareholders.

First Albany Capital acted as exclusive financial advisor to BioHorizons in this transaction.

BioHorizons Implant Systems, Inc.
Founded in 1994, BioHorizons has a strong product offering of dental implants including internal hex, external hex, overdenture and one-piece implants. BioHorizon's flagship External Implant System, a patented system of dental implants and related products, was launched in 1997. BioHorizons has signed exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. The Company has a direct sales force in the U.S., Canada, Germany, Spain and United Kingdom. Products are distributed in the rest of the world via a network of independent distributors.

HealthPointCapital
HealthPointCapital Partners II, L.P. is a values-driven, research-based private equity firm exclusively focused on the orthopedic and dental device businesses. HealthPointCapital has $500 million of institutional capital under management.


2000 Press Releases
16 august
LifeCell Signs Agreement With BioHorizons Implant Systems to Distribute AlloDerm in the Dental Market

BRANCHBURG, N.J.-- Aug. 16, 2000 / BUSINESS WIRE / --

LifeCell Corporation (Nasdaq:LIFC) and BioHorizons Implant Systems Inc., a privately held company that develops, manufactures and distributes oral reconstructive devices, today announced an agreement granting BioHorizons the exclusive right for the distribution of AlloDerm® to the dental market. BioHorizons, based in Birmingham, Ala., will distribute AlloDerm® to periodontists, oral and maxillofacial surgeons and dental schools for use in dental surgeries and bone regeneration procedures in the United States, Canada, Taiwan, Singapore, Australia and South Korea. AlloDerm® is currently distributed in the US and abroad, however, the new distribution agreement is part of a strategic plan to expand our customer base.

"It was apparent from the beginning that LifeCell and BioHorizons would make a strong team," said Paul G. Thomas, LifeCell's president and chief executive officer. "We are two companies that share an important commonality, which is our commitment to bring to market innovative medical products that benefit both patients and surgeons. We believe this alliance will push AlloDerm® to a new level and help the product reach its full potential in the dental market." AlloDerm® is human tissue that is processed through a patented system to remove all cells while preserving the bioactive proteins and structure of human dermis. This process and the extensive pre-process screening enhance the safety of the product. In dentistry, AlloDerm® is used primarily for correcting mucogingival defects and as a covering to protect bone grafts.

"We are excited about the opportunity to distribute AlloDerm® to our customer base," said Steve Boggan, BioHorizons' president and chief executive officer. "The combination of LifeCell's unique product with its proven success in a number of dental procedures, the BioHorizons customer base and BioHorizons' complementary bone grafting product line will expand the market for AlloDerm®." BioHorizons has a proven track record for developing its own dental implants and bone regeneration products and successfully marketing each of them to a full range of dental professionals. In addition, BioHorizons markets the Grafton® bone grafting products for Osteotech. BioHorizons replaces Lifecore Biomedical, which distributed AlloDerm® to the dental market for LifeCell since 1997. The agreement with Lifecore expired July 30, 2000.

About BioHorizons Implant Systems Inc.
BioHorizons Implant Systems develops, manufactures and distributes a broad range of oral reconstructive devices for dentistry and bone regeneration. The company introduced its flagship product an innovative, patented dental implant system called The Maestro System™, in 1997. Since it has expanded their product offering to provide a full spectrum of bone regeneration tools, including the distribution of Grafton, which is processed by Osteotech. BioHorizons distributes its products through a direct sales force to periodontists, orthodontists, general dentists and oral surgeons throughout the US and through a network of distributors for international markets.

About LifeCell Corporation
LifeCell Corporation, a leader in the emerging field of regenerative medicine, is engaged in developing and marketing biologic solutions for the repair, replacement and preservation of human tissues. The company's core preservation technology produces an acellular tissue matrix, which retains the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets three products based on its tissue matrix technology: AlloDerm® for the plastic reconstructive and burn markets through LifeCell's direct sales force and for the dental market through BioHorizons Implant Systems Inc.; Cymetra™ for the plastic reconstructive and dermatology markets through LifeCell's direct sales force and a co-promotion agreement with Obagi Medical Products; and Repliform™ for the urogynecology market through the company's partnership with Boston Scientific Corporation. The company's product development programs include a small diameter vascular graft as an alternative to autografted blood vessels, orthopedic applications of its acellular dermal matrix and Thrombosol™, a formulation for extended storage of platelets.

Certain of the statements contained in this news release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). While these statements reflect the company's current beliefs and are based on assumptions that the company believes are reasonable, they are subject to uncertainties and risks that could cause actual results to differ materially from anticipated results. These factors include, but are not limited to, the uncertainty of product development, of clinical trials, of regulatory approval and of patent protection; the demand for the company's products and services; economic and competitive conditions and product and other risks detailed in the company's Annual Report on Form 10-K for the year ended Dec. 31, 1999, and other reports filed with the Securities and Exchange Commission.